Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow
Use
Risk stratification of patients with treated and newly diagnosed multiple myeloma can assist in determining treatment and management decisions. This approach classifies patients into standard or high-risk categories based on plasma cell proliferation and fluorescence in situ hybridization results for specific multiple myeloma-associated abnormalities.
Special Instructions
Not provided.
Limitations
This test is best used for newly diagnosed patients with multiple myeloma. It may not be applicable for monoclonal gammopathy of uncertain significance, smoldering myeloma, or amyloidosis. The stratification system is not meant to replace existing prognostic systems such as the International Staging System.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 93363-0 - PC DNA content + prolif Pnl Mar FC
- 93362-2 - Monotypic plasma cells Mar FC
- 93021-4 - PC.abnormal/Cells NFr Mar FC
- 93361-4 - Mono PC in S Phs NFr Mar FC
- 93360-6 - Monotypic PC DNA index Mar FC-Rto
- 93359-8 - Monotypic PC DNA ploidy Mar FC
- 93358-0 - Polyclonal PCs/Cells NFr Mar FC
- 93020-6 - Polyclonal PCs/Total PCs NFr Mar FC
- 22637-3 - Path report.final Dx Spec
Result Turnaround Time
1-11 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
4 mL
Minimum Volume
3 mL
Container
Yellow top (ACD solution A or B); Acceptable: Lavender top (EDTA) or green top (heparin)
Storage Instructions
Ambient (preferred), Refrigerated (acceptable for up to 72 hours)
Causes for Rejection
Gross hemolysis and fully clotted specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |